Valbiotis SA

Paris Stock Exchange ALVAL.PA

Valbiotis SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 13.79 M

Valbiotis SA Net Cash Used Provided By Financing Activities is USD 13.79 M for the year ending December 31, 2023, a 53.42% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Valbiotis SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 8.99 M, a -45.16% change year over year.
  • Valbiotis SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 16.39 M, a 220.14% change year over year.
  • Valbiotis SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 5.12 M, a -22.02% change year over year.
  • Valbiotis SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 6.57 M, a 174.46% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
Paris Stock Exchange: ALVAL.PA

Valbiotis SA

CEO Mr. Sebastien Peltier HDR, Ph.D.
IPO Date June 7, 2017
Location France
Headquarters rue Paul Vatine
Employees 52
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Non-Alcoholic Beverages Pet Food Snack Foods Soft Drinks & Sodas Vaccines
Description

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

Similar companies

OSE.PA

OSE Immunotherapeutics SA

USD 6.63

-0.22%

StockViz Staff

February 7, 2025

Any question? Send us an email